demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
secondary prevention
adjuvant therapies
anticoagulant
rivaroxaban MICHELLE

16 studies excluded by filtering options 2

5156 Teleman, 2004 2200excludednot a RCTrisk of bias not avaialble
5157 Wu, 2004 2200excludednot a RCTrisk of bias not avaialble
5158 Loeb, 2004 2200excludednot a RCTrisk of bias not avaialble
5159 Wilder-Smith, 2005 2200excludednot a RCTrisk of bias not avaialble
5160 Wang, 2020 2200excludednot a RCTrisk of bias not avaialble
5162 Cheng, 2010 2200excludednot a RCTrisk of bias not avaialble
5164 Jaeger, 2011 2190excludednot a RCTrisk of bias not avaialble
5167 Chokephaibulkit, 2012 2200excludednot a RCTrisk of bias not avaialble
5168 Zhang, 2012 2200excludednot a RCTrisk of bias not avaialble
5169 Sung, 2016 2130excludednot a RCTrisk of bias not avaialble
5170 Zhang, 2017 2200excludednot a RCTrisk of bias not avaialble
5172 Ma, 2004 2200excludednot a RCTrisk of bias not avaialble
5173 Yin, 2004 2200excludednot a RCTrisk of bias not avaialble
5176 Zhang, 2013 2130excludednot a RCTrisk of bias not avaialble
5177 Nishiura, 2005 2200excludednot a RCTrisk of bias not avaialble
6405 Li [retracted], 2020 200excludedrisk of bias not avaialble